Lobbying registration dated 2026-03-05
Registrant: WILLIAM DEMPSTER
Client: Vertex Pharmaceuticals (Canada) Inc.
Targeted institutions:
Justice Canada (JC)
Finance Canada (FIN)
Treasury Board Of Canada Secretariat (TBS)
Prime Minister's Office (PMO)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Global Affairs Canada (GAC)
Public Health Agency of Canada (PHAC)
Patented Medicine Prices Review Board (PMPRB)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Legislative bills: S-201
Acts: Pharmacare Act
Food and Drugs Act
Government funding received:
Lobbying activity details:
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
Implementation of Canada's action plan for pain and federal initiatives related to pain management.
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.